ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Delaware » Pulmonary Disease

Top Pulmonary Disease Prescribers in Delaware

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
MARK GRANADA MD

Pulmonary Disease

8,461

$565K

285
200 are 65+

6%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 68%

$67
Average prescription price

Avg: $211

MICHEL SAMAHA M.D.

Pulmonary Disease

2,533

$691K

307
224 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 68%

$273
Average prescription price

Avg: $211

ANTHONY VASILE D.O.

Pulmonary Disease

2,310

$509K

334
258 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 68%

$220
Average prescription price

Avg: $211

BRIAN WALSH D.O.

Pulmonary Disease

1,722

$288K

233
156 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

55%
prescriptions for brand name drugs

Avg: 68%

$168
Average prescription price

Avg: $211

ERCILIA ARIAS M.D.

Pulmonary Disease

1,635

$331K

250
213 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 68%

$203
Average prescription price

Avg: $211

DAVID JAWAHAR MD

Pulmonary Disease

1,621

$507K

289
190 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 68%

$313
Average prescription price

Avg: $211

HUMMAYUN ISMAIL M.D.

Pulmonary Disease

1,462

$248K

195
128 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 68%

$169
Average prescription price

Avg: $211

ADITYA DUBEY MD

Pulmonary Disease

1,450

$372K

181
117 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

77%
prescriptions for brand name drugs

Avg: 68%

$257
Average prescription price

Avg: $211

JOHN GOODILL MD

Pulmonary Disease

1,309

$232K

127
81 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

54%
prescriptions for brand name drugs

Avg: 68%

$178
Average prescription price

Avg: $211

VIKAS BATRA M.D.

Pulmonary Disease

1,236

$314K

266
204 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 68%

$254
Average prescription price

Avg: $211

ALBERT RIZZO MD

Pulmonary Disease

1,096

$204K

159
122 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

60%
prescriptions for brand name drugs

Avg: 68%

$186
Average prescription price

Avg: $211

MUHAMMAD ATHAR MD

Pulmonary Disease

1,085

$268K

166
115 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

74%
prescriptions for brand name drugs

Avg: 68%

$247
Average prescription price

Avg: $211

CLIFTON HUNT MD

Pulmonary Disease

1,032

$369K

242
209 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 68%

$358
Average prescription price

Avg: $211

JOHN CHABALKO MD

Pulmonary Disease

1,019

$193K

133
92 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

79%
prescriptions for brand name drugs

Avg: 68%

$189
Average prescription price

Avg: $211

JOSEPH KESTNER MD

Pulmonary Disease

913

$203K

139
105 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

83%
prescriptions for brand name drugs

Avg: 68%

$223
Average prescription price

Avg: $211

MARK JONES MD

Pulmonary Disease

788

$241K

102
86 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

74%
prescriptions for brand name drugs

Avg: 68%

$305
Average prescription price

Avg: $211

MADAN JOSHI M.D.

Pulmonary Disease

610

$139K

107
74 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 68%

$227
Average prescription price

Avg: $211

TUHINA RAMAN M.D.

Pulmonary Disease

508

$130K

92
72 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

87%
prescriptions for brand name drugs

Avg: 68%

$256
Average prescription price

Avg: $211

GHAZALA FAROOQUI MD

Pulmonary Disease

497

$90.2K

73
55 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 68%

$181
Average prescription price

Avg: $211

VICTOR BANZON

Pulmonary Disease

475

$77K

124
99 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 68%

$162
Average prescription price

Avg: $211

ALEJANDRO SARDI-FREITEZ MD

Pulmonary Disease

440

$90.6K

95
64 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

73%
prescriptions for brand name drugs

Avg: 68%

$206
Average prescription price

Avg: $211

DONALD COLLINS MD

Pulmonary Disease

399

$65.5K

60
38 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

51%
prescriptions for brand name drugs

Avg: 68%

$164
Average prescription price

Avg: $211

GERALD O'BRIEN MD

Pulmonary Disease

396

$883K

57
41 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 68%

$2230
Average prescription price

Avg: $211

FARID MOOSAVY MD

Pulmonary Disease

334

$59.2K

63
47 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

83%
prescriptions for brand name drugs

Avg: 68%

$177
Average prescription price

Avg: $211

CAROLE GUY M.D.

Pulmonary Disease

322

$55.2K

55
39 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 68%

$171
Average prescription price

Avg: $211

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank